Goldman Sachs Sees Big Gains From 7 Biotech & Pharma Conviction Buy Stocks
Goldman Sachs has seven biopharma stocks on its Conviction Buy list, and these are not all coronavirus plays. The firm thinks these stocks could go on the offensive for the rest of…